OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $823,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 245,800 shares of the company’s stock, valued at approximately $823,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.67% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics in the fourth quarter valued at about $68,000. XTX Topco Ltd bought a new position in VYNE Therapeutics in the fourth quarter worth approximately $70,000. Bridgeway Capital Management LLC purchased a new stake in VYNE Therapeutics during the fourth quarter worth $124,000. Adage Capital Partners GP L.L.C. bought a new stake in VYNE Therapeutics during the 4th quarter valued at $516,000. Finally, Schonfeld Strategic Advisors LLC boosted its position in VYNE Therapeutics by 4.8% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after acquiring an additional 8,058 shares in the last quarter. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Stock Performance

NASDAQ:VYNE opened at $1.31 on Wednesday. The company’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $2.39. VYNE Therapeutics Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $4.30. The stock has a market capitalization of $19.93 million, a P/E ratio of -1.52 and a beta of 1.76.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.05 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. On average, research analysts forecast that VYNE Therapeutics Inc. will post -0.97 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating for the company in a research report on Friday, April 25th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.